BOSTON – The triumph of the Massachusetts Institute of Technology Broad Institute and its spinout company Editas Medicine Inc. in the case of CRISPR/Cas9 gene editing patents could impede the development of human therapies based on the technology, according to one of the leading researchers in the field.
In a single sentence, the U.S. PTO rendered a judgment of "no interference-in-fact" in CRISPR/Cas9 interference motion phase, neither canceling nor finally refusing the claims of either party.
LONDON – Clinical trials involving genome editing in gametes or early embryos could be permitted in the future, but only for serious conditions and under stringent oversight, said experts after a year-long review of the scientific and ethical issues thrown up by CRISPR/Cas9.
- Verma cites choice, competition in Senate confirmation hearing
- Ionis/Akcea tie $1.6B knot; CV bid with Novartis adds to better spin on Spinraza
- 'Ideology crowding out facts'; AAAS CEO stresses need to talk about science
- A fine red line between cures, enhancements using gene editing tech
- Valeant wins FDA approval for Siliq
- Singapore's Aslan readies for Taiwan listing, capital raise for cancer pipeline
- Industry bemoans lack of incentives despite biotech budget hike
- PhRMA: More dialogue in Japan to balance innovation, drug pricing
- As Nesp patent nears expiration, Kirin sets up new biosimilar firm
- Taiwan's Senhwa tackles cholangiocarcinoma, gets...
As Rare Disease Day approaches, there's plenty to celebrate. The acquisition of Baxalta Inc. by Shire plc early in 2016 created a global giant with an equally large appetite for therapies to treat rare indications. Last year saw a huge, albeit controversial, breakthrough to treat Duchenne muscular dystrophy (DMD) with accelerated approval of Sarepta Therapeutics Inc.'s exon-skipping drug, eteplirsen, branded Exondys 51. And as the year ended, passage of the 21st Century Cures Act – encompassing patient-focused drug development, qualification of biomarkers and other development tools, and novel clinical trial designs – became a legislative triumph for the rare disease community.
LONDON Clinical trials involving genome editing in gametes or early embryos could be permitted in the future, but only for serious conditions and under stringent oversight, said experts after a year-long review of the scientific and ethical issues thrown up by CRISPR/Cas9.READ MORE »
- Bacterial immunotherapy shows promise in tumor-targeting »
- 'Bioinspired' culturing process loses serum, gains reproducibility »
- First rotaviruses derived entirely from cloned DNA developed »
- Clotting, hypertension, inflammation linked »
- Plant-derived products may help fight HBV »
- New targets for overcoming melanoma resistance identified »
- Dual-action, dual-indication decoy fights tumors, viruses »
- Stem cell-based model suggests deafness treatments »
- Stabilizing MLL fights fusion proteins' effects »
- Is ‘what the patient pays’ the right barometer for pricing drugs?January 26, 2017 | 5:08 PM | Posted by: Mari Serebrov
- Yes, there’s a doctor in the House (and Senate)January 04, 2017 | 12:21 AM | Posted by: Mari Serebrov
- Time for fa-la-la with BioWorld’s 10th annual Holiday Gift GuideDecember 02, 2016 | 8:43 PM | Posted by: Marie Powers
- Biotech’s biggest protesters are turning into its supporters November 30, 2016 | 10:58 PM | Posted by: Amanda Lanier
- Sex and drugs: Something doesn’t ‘Addyi’ upNovember 04, 2016 | 10:35 PM | Posted by: Randy Osborne
Partners in Focus
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST